Debt Investors

Home / Investor relations / Debt Investors

Funding strategy

  • The Board reviews the Company’s ongoing liquidity risks annually as part of the planning process and on an ad-hoc basis.
  • The Board considers short-term requirements against available sources of funding, taking into account forecast cash flows.
  • The Company manages liquidity risk by maintaining access to a number of sources of funding which are sufficient to meet anticipated funding requirements.
  • Specifically, the Company uses US commercial paper and/or Euro-commercial paper programmes, committed bank facilities and cash resources to manage short-term liquidity.
  • The Company maintains strong access to the capital markets for long-term funding through an established Euro Medium Term Note (EMTN) programme and a SEC registered shelf programme.
  • The Company has $4.9bn of revolving committed credit facilities provided by 13 relationship banks. These facilities were undrawn at 30 June 2026 and are available until April 2031.
  • These different funding programmes ensure that the Company has sufficient flexibility when choosing the maturity, currency, interest rate (fixed/floating), and geographical mix of investors.

 

Programme Last updated Valid to Limit Rating (Moody's/ S&P) Utilisation as at 30 June 2026

US Commercial Paper

N/A

N/A

USD 15bn

A-1 / P-1

USD 2.4bn

Euro-Commercial Paper

12 May 2020

N/A

EUR 10bn

Issuer rating

None

Euro Medium Term Note Programme

June 2026

June 2027

Unlimited

A1 / A+

USD 5.6bn

SEC Shelf Registration Statement

Mar 2024

Mar 2027

Unlimited

A1 / A+

USD 21.0bn

Debt maturity profile

AstraZeneca chooses to hold a significant cash balance to meet operational funding needs. Gross cash and investments position as at 30 June 2026 was $5.0bn

1  Notional bond values. FX converted at 30 June 2026 spot rates (USD/EUR 0.876; USD/GBP 0.755). Current portion of leases of $426m are included in 2026, whilst non-current Leases of $2,322m have been excluded from the chart.

Outstanding bonds

Below is a summary of the bonds issued or guaranteed by AstraZeneca PLC as at 2 September 2026 sorted by maturity date.

Issuer Currency Notional (m) Issue date Maturity date Coupon Frequency ISIN Note
AZ Finance LLC USD 1,250 26-Feb-24 26-Feb-27 4.80% Semi-annual US04636NAK90  
AZ PLC EUR 750 03-Mar-23 03-Mar-27 3.625% Annual XS2593105393 1
AZ PLC USD 750 12-Jun-17 12-Jun-27 3.125% Semi-annual US046353AN82  
AZ Finance LLC USD 1,100 03-Mar-23 03-Mar-28 4.875% Semi-annual US04636NAF06  
AZ PLC EUR 800 12-May-16 12-May-28 1.25% Annual XS1411404426 2
AZ Finance LLC USD 1,250 28-May-21 28-May-28 1.75% Semi-annual US04636NAE31  
AZ PLC USD 1,000 17-Aug-18 17-Jan-29 4.00% Semi-annual US046353AT52  
AZ Finance LLC USD 1,250 26-Feb-24 26-Feb-29 4.85% Semi-annual US04636NAL73  
AZ PLC EUR 800 03-Jun-21 03-Jun-29 0.375% Annual XS2347663507 3
AZ Finance LLC EUR 700 01-Sep-26 01-Mar-30 3.402% Annual XS3484302206 4
AZ Finance LLC USD 650 03-Mar-23 03-Mar-30 4.90% Semi-annual US04636NAG88  
AZ Finance LLC EUR 650 05-Aug-24 05-Aug-30 3.121% Annual XS2872909697 5
AZ PLC USD 1,300 06-Aug-20 06-Aug-30 1.375% Semi-annual US046353AW81  
AZ Finance LLC USD 1,000 26-Feb-24 26-Feb-31 4.90% Semi-annual US04636NAM56  
AZ Finance LLC USD 650 02-Mar-26 02-Mar-31 4.00% Semi-annual US04636NAQ60

 

AZ Finance LLC USD 750 28-May-21 28-May-31 2.25% Semi-annual US04636NAB91  
AZ PLC GBP 350 13-Nov-07 13-Nov-31 5.75% Annual XS0330497149 3
AZ Finance LLC EUR 600 01-Sep-26 01-Sep-32 3.652% Annual XS3484302461 6
AZ PLC EUR 750 03-Mar-23 03-Mar-32 3.75% Annual XS2593105476 7
AZ Finance LLC USD 600 02-Mar-26 02-Mar-33 4.30% Semi-annual US04636NAR44  
AZ Finance LLC USD 500 03-Mar-23 03-Mar-33 4.875% Semi-annual US04636NAH61  
AZ Finance LLC EUR 750 05-Aug-24 05-Aug-33 3.278% Annual XS2872909770 8
AZ Finance LLC USD 1,500 26-Feb-24 26-Feb-34 5.00% Semi-annual US04636NAN30  
AZ Finance LLC EUR 500 01-Sep-26 01-Sep-35 3.923% Annual XS3484302545 9
AZ Finance LLC USD 750 02-Mar-26 02-Mar-36 4.60% Semi-annual US04636NAS27  
AZ PLC USD 2,750 12-Sep-07 15-Sep-37 6.45% Semi-annual US046353AD01  
AZ Finance LLC EUR 750 01-Sep-26 01-Sep-38 4.169% Annual XS3484302628 10
AZ PLC USD 1,000 18-Sep-12 18-Sep-42 4.00% Semi-annual US046353AG32  
AZ PLC USD 1,000 16-Nov-15 16-Nov-45 4.375% Semi-annual US046353AM00  
AZ PLC USD 750 17-Aug-18 17-Aug-48 4.375% Semi-annual US046353AU26  
AZ PLC USD 500 06-Aug-20 06-Aug-50 2.125% Semi-annual US046353AX64  
AZ PLC USD 750 25-May-21 28-May-51 3.00% Semi-annual US046353AZ13  

 

1 Swapped to approximately USD 791m at approximately 4.91%, semi-annual payments

2 Swapped to approximately USD 912m at approximately 3.06%, semi-annual payments

3 In a net investment hedge relationship. For more details, please refer to note 28 of our Annual Report and Form 20-F Information 2023.

4 Swapped to approximately USD 817m at approximately 4.72%, semi-annual payments

5 Swapped to approximately USD 704m at approximately SOFR + 0.80%, quarterly payments

6 Swapped to approximately USD 700m at approximately 4.99%, semi-annual payments

7 Swapped to approximately USD 791m at approximately 4.83%, semi-annual payments

8 Swapped to approximately USD 812m at approximately SOFR + 0.95%, quarterly payments

9 Swapped to approximately USD 584m at approximately 5.27%, semi-annual payments

10 Swapped to approximately USD 875m at approximately SOFR + 1.10%, quarterly payments

 

 

Credit ratings

AstraZeneca PLC aims to maintain a strong, investment grade credit rating. The Company has solicited credit ratings from Moody’s and S&P, which are assigned as:

  Moody's
S&P
Short-term rating P-1 A-1
Long-term rating A1 A+
Outlook Positive Stable


Key contacts at the respective agencies are:

Moody’s

Analyst: Maria Maslovsky

Phone: +44 207 772 5502

S&P

Analyst: Nikolay Popov

Phone: +44 7483 981766

Treasury risk management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.
 

Liquidity Policy

  • Prudent level of available cash and unutilised credit facilities
  • Group funding centrally managed
     

Investment policy

  • Security and liquidity
  • Financial counterparty limits
     

Foreign Exchange Policy

  • Foreign Exchange exposures managed centrally
  • Transactional currency exposures substantially hedged
     

Interest Rate Policy

  • Aim to broadly match level of floating rate debt to cash over time
  • Significant portion of financial liabilities at fixed interest rates
     

Credit Risk

  • Cash managed centrally
  • Derivatives positions predominately cash collateralised

Debt IR presentations

Press Releases

FMSB Statement of Commitment



Contact Us


Christer Gruvris

Director of Investor Relations

Jonathan Slade

Group Treasurer


  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development


  • Shareholder FAQs

    Answers to frequently asked shareholder questions.